LLY
Eli Lilly and Company
LLY has the edge over TDOC overall, supported by stronger fundamentals and lower modeled downside.
TDOC
Teladoc Health, Inc.
TDOC's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
TDOC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Healthy | |
| Healthy |
TDOC's cash flow and balance sheet are currently healthy, and its revenue is stable, but its profitability is under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
TDOC PE Valuation
TDOC has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over TDOC on the outlook, with more favorable revenue expectations.
TDOC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect TDOC's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over TDOC on earnings quality, reporting a profit while its opponent remains loss making.
TDOC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.86 | +$0.41 |
| Q2 2026 | -$0.99 | +$0.19 |
| Q1 2026 | -$0.97 | +$4.94 |
| Q4 2025 | -$1.14 | +$4.73 |
| Q3 2025 | -$1.27 | +$4.50 |
| Q2 2025 | -$1.18 | +$4.75 |
| Q1 2025 | -$5.91 | -$4.50 |
| Q4 2024 | -$5.87 | -$4.53 |
TDOC is still losing money, but far less than before: $0.86 per share over the past year, against $84.60 at its worst in late 2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over TDOC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over TDOC on profitability, with a higher operating margin.
TDOC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $605.1M | -3.4% |
| Q2 2026 | $606.9M | -4% |
| Q1 2026 | $613.8M | -2.5% |
| Q4 2025 | $642.3M | +0.3% |
| Q3 2025 | $626.4M | -2.2% |
| Q2 2025 | $631.9M | -1.6% |
| Q1 2025 | $629.4M | -2.6% |
| Q4 2024 | $640.5M | -3% |
TDOC's revenue grew through 2022 and has held roughly level since: $605M last quarter, down 3.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -4.6% | +3.6 points |
| Q2 2026 | -6.1% | +2.5 points |
| Q1 2026 | -10% | +9.1 points |
| Q4 2025 | -5.6% | +1.9 points |
| Q3 2025 | -8.3% | -1.4 points |
| Q2 2025 | -8.6% | +122 points |
| Q1 2025 | -19% | -5.7 points |
| Q4 2024 | -7.5% | -2.2 points |
TDOC's operating margin was −4.6% last quarter, up 3.6 points from the same quarter a year ago, near the top of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over TDOC on cash flow, with more consistent year-over-year improvement.
TDOC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $105.2M | +8.5% |
| Q2 2026 | $63.7M | -29% |
| Q1 2026 | $7.9M | -40% |
| Q4 2025 | $85.1M | +6.7% |
| Q3 2025 | $97M | -11% |
| Q2 2025 | $90.2M | +3.9% |
| Q1 2025 | $13.2M | +70% |
| Q4 2024 | $79.8M | -38% |
TDOC generated $262M in free cash flow over the past year, down 6.5% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over TDOC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
TDOC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +850K shares |
| 1 year | +2.8% | +4.9M shares |
| 3 years | +10% | +16.8M shares |
| 5 years | +14% | +22.4M shares |
| Available history | +151% | +109M shares |
TDOC has 182M diluted shares, up 2.8% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
TDOC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.1x | Net Cash |
| Q2 2026 | -4.3x | Net Cash |
| Q1 2026 | -4.6x | Net Cash |
| Q4 2025 | -7.7x | Net Cash |
| Q3 2025 | -8.7x | Net Cash |
| Q2 2025 | -7.4x | Net Cash |
TDOC has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
TDOC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.1 | Neutral |
| Stochastic | 75.8 | Neutral |
TDOC's weekly RSI is 63 (neutral) and its Stochastic is 76 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
TDOC PE vs Healthcare Sector
TDOC has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over TDOC on trend strength, trading above more of its moving averages.
TDOC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.92 | 26% above |
| 20 week MA | $7.22 | 20% above |
| 50 week MA | $6.68 | 30% above |
| 100 week MA | $7.51 | 16% above |
| 200 week MA | $12.6 | 31% below |
TDOC has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 31% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over TDOC on returns for 2026, with the stronger performance.
TDOC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $83.4 | $208.0 | +149% |
| 2021 | $208.0 | $95.1 | -54% |
| 2022 | $95.1 | $23.5 | -75% |
| 2023 | $23.5 | $21.6 | -8.4% |
| 2024 | $21.6 | $9.45 | -56% |
| 2025 | $9.45 | $7.12 | -25% |
| 2026 YTD | $7.12 | $8.69 | +22% |
TDOC has finished five years in a row lower, and it's up 22% so far in 2026.